Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in a series of disappointing industry developments in sickle cell disease.
The post Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint appeared first on MedCity News.
